Daniel Crisci Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 7922 Barristers Ct, Kirtland, OH 44094 Phone: 440-796-7491 |
Mrs. Mia Katherine Shaw, OTD, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 9410 Chillicothe Rd, Kirtland, OH 44094 Phone: 234-380-9414 |
Aaron Humphrey Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 9685 Chillicothe Rd, Kirtland, OH 44094 Phone: 440-256-8100 Fax: 440-256-8104 |
News Archive
Struggling to curb that cigarette habit? A new study has found that people trying quit smoking may benefit from inhaling pleasant-smelling aromas like peppermint, chocolate, or vanilla.
Health Net Federal Services, LLC, the government operations division of Health Net, Inc., today announced it recently received multiple MarCom Awards for its education and communication materials from the Association of Marketing & Communication Professionals (AMCP). AMCP is an international organization of thousands of creative professionals, recognizing the best materials and resources in the business through its MarCom Awards.
SNM recently conducted a survey of nuclear pharmacies-pharmacies that supply the critical radioisotope Technetium-99m, which is used in more than 16 million nuclear medicine tests each year in the United States-to assess, anecdotally, the impact of the worldwide medical isotope shortage. According to the survey, 60 percent of radiopharmacies have been impacted by the most recent shortage. Technetium-99m is a product of Molybdenum-99, which has been in short supply recently.
Lee Ryan, 74, a Worth, Illinois man was among the first in Chicago to receive a MRI-compatible pacemaker. His pacemaker was implanted at MetroSouth Medical Center, a hospital known for its excellent cardiac care.
Taiho Pharmaceutical Co., Ltd., and its parent company, Otsuka Holdings Co., Ltd., announced today that the Committee for Medicinal Products for Human Use (CHMP), a division of the European Medicines Agency (EMA), has issued an opinion recommending approval of Teysuno™ (S-1), a novel oral anti-cancer agent, intended for the treatment of advanced gastric cancer in adults when given in combination with cisplatin.
› Verified 5 days ago